6533b826fe1ef96bd1284680

RESEARCH PRODUCT

Synthetic MUC1 Antitumor Vaccine Candidates with Varied Glycosylation Pattern Bearing R/S-configured Pam3 CysSerLys4.

Lei ShiYan-mei LiYufen ZhaoZhi-hua HuangYong-xiang ChenHorst KunzHui CaiZhan-yi Sun

subject

GlycosylationGlycosylationLipoproteins010402 general chemistry01 natural sciencesBiochemistryCancer VaccinesEpitopechemistry.chemical_compoundMiceImmune systemAnimalsHumansMolecular BiologyMUC1Solid-Phase Synthesis TechniquesMice Inbred BALB CVaccines SyntheticInnate immune systembiology010405 organic chemistryOrganic ChemistryMucin-1GlycopeptidesImmunityLipopeptideStereoisomerismVirologyGlycopeptide0104 chemical scienceschemistrybiology.proteinMCF-7 CellsMolecular MedicineAntibody

description

The Toll-like receptor 2 ligand Pam3 CysSer is of particular interest for the construction synthetic vaccines because of its ability to stimulate of the innate immune system. Such vaccines usually comprise Pam3 CysSer with the natural R-configuration at the glycerol 2-position. Pam3 CysSer peptide vaccines with natural configuration have been shown to be more efficient than the corresponding R/S diastereomers. In order to clarify whether the effect of the configuration of Pam3 Cys on the immune response also applies to glycopeptide vaccines, MUC1 glycopeptide-lipopeptide vaccines bearing either R- or R/S-configured Pam3 CysSerLys4 were compared for their immunological effects. In order to find out whether glycosylated MUC1 tandem repeat domains comprise not only B-cell epitopes but also T-cell epitopes, two-component vaccines containing the Pam3 CysSerLys4 lipopeptide and MUC1 glycopeptides with various glycosylation patterns were synthesized, and their immune reactions in mice were studied.

10.1002/cbic.201600206https://pubmed.ncbi.nlm.nih.gov/27188544